Imbalance between T regulatory (Treg) and T effector (Teff) cells is likely to contribute to the induction and perpetuation of liver damage in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability of Tregs to restrain proliferation and effector cytokine production by responders or through conversion of Tregs into T helper type 1 (Th1) or type 17 (Th17) effector lymphocytes. We investigated the effect of Treg skewing on the phenotypic and functional properties of CD4 A utoimmune hepatitis type 1 (AIH-1) and autoimmune sclerosing cholangitis (AISC) are forms of autoimmune liver disease in which hypergammaglobulinemia and positivity for anti-nuclear and/or anti-smooth muscle antibody (SMA) coexist with evidence of interface hepatitis on histology and, in the case of AISC, bile duct abnormalities.
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In AIH and AISC, numerical and functional defects of CD4 1 CD25 high FOXP3 1 (forkhead box P3) regulatory T cells (Tregs) are associated with overwhelming T helper type 1 (Th1) and type 17 (Th17) effector responses (Teff). (3) (4) (5) Imbalance between Tregs and Teff has been found to contribute to the perpetuation of tissue injury in AIH and AISC because of an inability of Tregs to control the proliferation and effector cytokine production by Teff and because of acquisition of Teff properties by Tregs. (6, 7) A wealth of studies have provided evidence that Tregs and Teff are not terminally differentiated lymphocyte subsets but are both susceptible to phenotypic and functional plasticity. Thus, exposure of Tregs to proinflammatory cytokines promotes conversion into Th17 cells (8) or acquisition of Th1 effector properties, including production of interferon gamma (IFNc). (9) On the other hand, transdifferentiation of Th17 into interleukin 10 (IL-10)-producing T regulatory 1 (Tr1) cells has been reported in the small intestine, in the setting of experimental colitis induced either by anti-CD3 monoclonal antibody treatment or infectious agents. (10, 11) We previously reported that Tregs isolated from the peripheral blood of AIH patients are prone to acquire effector properties when exposed to proinflammatory mediators like IL-6 and IL-1b, which are abundantly produced by CD4 Teff in AIH. (12) Despite retaining a Treg phenotype, these cells produce IFNc and IL-17, participate in the maintenance of the Teff pool, and contribute to the perpetuation of hepatic damage in AIH. However, we have demonstrated that in vitro blockade of IL-17 can favor de novo generation of Tregs that are phenotypically stable upon proinflammatory challenge both in health and in AIH patients. (12) Collectively these studies support the concept that modulation of the cytokine and inflammatory environment can substantially affect the phenotypic and functional properties of both Teff and Tregs. In this context activated Teff expressing high levels of CD25 and CD127 are of particular interest. Levels of CD127, the IL-7 receptor a chain normally present on activated Teff, (13) correlate negatively with the expression of FOXP3 as a result of FOXP3 binding to the CD127 promoter. (14) However, though expression of CD127 normally denotes an effector phenotype, CD127
1 cells can acquire functional properties of suppressive cells upon modulation of the cytokine environment, (15) suggesting the possibility of deriving Tregs from Teff.
In the present study, we investigated the effect of Treg skewing on the phenotypic and functional properties of the CD4

CD127
1
CD25
high Teff subset in patients with AIH and AISC.
Patients and Methods
SUBJECTS
Thirty-two patients with AIH-1 and 20 with AISC were studied. All were anti-nuclear antibody-positive and/or SMA-positive at presentation. A liver biopsy performed at the time of or close to diagnosis showed histopathological features of interface hepatitis in all patients. AISC patients were diagnosed on the basis of bile duct changes of sclerosing cholangitis on retrograde cholangiography.
(2) Twenty-five patients (16 with AIH and 9 with AISC) were female. Twenty-one patients (6 with AIH and 15 with AISC) had inflammatory bowel disease, including 19 with ulcerative colitis and 2 with Crohn's disease; all 6 AIH patients had ulcerative colitis; 13 of the AISC patients had ulcerative colitis, and 2 had Crohn's. Thirty-two patients (20 with AIH and 12 with AISC) were studied during drug-induced remission (i.e., normal transaminase levels, [R]); 20 patients (12 with AIH and 8 with AISC) had active disease [A] at the time of study. In 6 [A] patients (4 with AIH and 2 with AISC), blood was obtained at disease presentation before the immunosuppression was started; the remaining 14 patients (8 with AIH and 6 with AISC) were studied during an episode of relapse while on stable maintenance treatment. Two patients in remission (both with AISC) were off immunosuppressive treatment at the time of study. Demographic and laboratory data of AIH and AISC patients are presented in Table  (1a and 1b) . Patients were treated with prednisolone (2.5-5 mg/day at remission and 1-2 mg/kg/day at relapse) either alone or in combination with azathioprine (1-2 mg/kg/day) or mycophenolate mofetil (MMF, up to 40 mg/kg/day). In AISC patients ursodeoxycholic acid at a dose of 15-20 mg/kg/day was added to the immunosuppressive regimen. Twentynine healthy subjects (HS, median age 28.9 years, range 22.6-39, 19 women) served as normal controls. The age difference between patients and HS was due to ethical constraints in obtaining blood from healthy children. The study was approved by the Ethics Committee of King's College Hospital, London; and written consent was obtained from each AIH or AISC patient or legal guardian and HS enrolled in the study.
CELL SEPARATION
Peripheral blood mononuclear cells (PBMCs) were obtained as described. (3) Mononuclear cell viability, determined by Trypan blue exclusion, exceeded 98%. The frequency of cells positive for FOXP3, T-bet, and related orphan receptor 3 (RORC) was determined by intracellular staining after cell fixation and permeabilization with Cytofix/Cytoperm (BD Bioscience) and counterstaining with fluorescein isothiocyanate or allophycocyanin-conjugated anti-FOXP3 (clone PCH101), peridinin chlorophyll proteincychrome 5-conjugated anti-T-bet, or PE-conjugated anti-RORC monoclonal antibodies (all from eBioscience, Hatfield, UK). The frequency of cells producing IFNc, IL-17, and IL-10 was assessed after exposure to phorbol 12-myristate 13-acetate (10 ng/ mL)/ionomycin (500 ng/mL) (both from SigmaAldrich Company Ltd., Gillingham, UK), incubation with brefeldin A (10 lg/mL; Sigma-Aldrich) for 5 hours, and counterstaining with AlexaFluor 488, PE, or allophycocyanin-conjugated anti-IL-17 (eBioscience), anti-IFNc (IQ Products, Groningen, The Netherlands), and anti-IL-10 (BD Bioscience) monoclonal antibodies. To assess the expression of the phospho signal transducer and activator of transcription 5 (pSTAT-5), cells were initially stained with fluorochrome-conjugated anti-CD4, CD25, and CD127 monoclonal antibodies and then treated with intracellular fixation buffer (eBioscience). After incubation at room temperature for 30 minutes and centrifugation at 600g for 5 minutes, ice-cold 100% methanol was added. After incubation at 48C for 30 minutes and washing, cells were stained with PEconjugated pSTAT-5 (Y694) monoclonal antibodies (eBioscience). Flow cytometry was performed as indicated above. 
FLOW CYTOMETRY
CELL PURIFICATION
CD25
high cells was consistently higher than 92% and 95%.
CELL POLARIZATION
Purified CD4
1 cells were exposed to Treg polarizing conditions, consisting of recombinant human transforming growth factor beta at 10 ng/mL, IL-2 at 100 U/mL, and anti-CD3/anti-CD28 T-cell expander (ratio bead/cell 1:2; Dynal Invitrogen). All recombinant cytokines were from R&D Systems. CD4
high cell phenotype, pSTAT-5 expression, and cytokine profile were analyzed by flow cytometry at baseline and following 4 days in culture in the presence of Treg polarizing conditions. The suppressive function of CD4 
CD25
high cells were tested as controls. Cells were cocultured at 378C and 5% CO 2 for 5 days in the presence of anti-CD3/anti-CD28 T-cell expander (ratio bead/cell 1:2) and IL-2 (30 U/mL). All experiments were performed in duplicate. For the last 18 hours cells were pulsed with 0.25 lCi/well 3 H-thymidine and harvested using a multichannel harvester. The percentage inhibition was calculated using the formula (1 - 
IL-2 AND IL-7 STIMULATION
Responsiveness of CD4 
CD25
high cells to IL-7 (10 ng/mL; R&D Systems) was assessed after 48 hours by 3 H-thymidine incorporation (see above). Control cultures, to which IL-2 or IL-7 was not added, were also included.
STATISTICAL ANALYSIS
The normality of variable distribution was assessed by the Kolmogorov-Smirnov goodness-of-fit test; once the hypothesis of normality was accepted (P > 0.05), comparisons were performed by paired or unpaired Student t test as appropriate. A one-way analysis of variance, followed by Tukey's multiple comparisons test, was used to compare means of multiple samples. Results are expressed as mean 6 standard error of the mean (SEM), unless otherwise stated; and P < 0.05 was considered significant. Data were analyzed using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA) and SPSS software (IBM, Hampshire, UK).
Results
INCREASE IN CD4
1 CD127 1 CD25 high
CELLS IN AIH AND AISC
We determined the frequency of CD4 cells that are positive for CD127 and concomitantly express high levels of CD25. CD4
high cell frequency was assessed in the peripheral blood of 32 patients, 18 [R] (AIH, R1-8, R10-11, R15-16 in Table 1a ; AISC, R2-4, R7-8, R12 in Table 1b ) and 14 [A] (AIH, A2-7, A9-10; AISC, A1-6), and in 14 HS. Cells were initially gated on CD4 lymphocytes, and then the proportion of CD127
1
CD25
high among these cells was measured (Fig. 1A) . The proportion of CD4 1 CD127 (Fig.  1B) . Among [A] patients no difference was noted between those studied at disease presentation, before immunosuppression was instituted, and those studied during an episode of relapse (Fig. 1C) . The frequency of CD4
1
CD25 high cells was higher in AIH/ AISC (both [A] and [R] patients) than in HS
1
CD127
1
CD25
high cells was similar in AIH and AISC patients (Fig. 1D ) and in AIH/AISC patients with and without inflammatory bowel disease (Fig. 1D) , suggesting that concomitant presence of bile duct damage or gut inflammation is not associated with heightened activation of CD4 T cells in the circulation. Percentage of CD4
1
CD127
1 CD25 high cells was correlated with levels of aspartate aminotransferase, total bilirubin, immunoglobulin G, and SMA autoantibody titer (Fig. 1E) . We also noted a trend toward significance when correlating the frequency of CD4 1 CD127
1
CD25
high cells with the number of relapse episodes (Fig. 1E) . Among treated AIH/AISC patients, we observed that those treated with a combination of prednisolone and MMF had the lowest proportion of CD4 
high cells (Fig. 1F) , indicating a differential impact of immunosuppressive drug regimens on this cell subset.
Collectively these data show that the proportion of activated CD4
high cells is elevated in AIH and AISC, especially during active disease; correlates with indices of disease activity; and is lowered when MMF is included in the immunosuppressive drug regimen. Fig. 2A) and of T-bet 1 cells (Fig. 2B ) but similar frequencies of RORC 1 and FOXP3 1 lymphocytes (Fig. 2B) . Because CD4 
high Tregs, (7) are unresponsive to low-dose IL-2, as expected we found no pSTAT-5 up-regulation in both patients (AIH, A9, R4-6, R10, R14 in Table 1a ; AISC, A5, R4 and R6-7 in Table 1b ) and HS (Fig.  2C) . The proliferative response of CD4
high cells after exposure to anti-CD3/anti-CD28 beads is higher in patients (AIH, A2, R4, R8, R11-12 in Table 1a ; AISC, R1 in Table 1b ) than HS (Fig.  2D ) and is further enhanced by stimulation with IL-7 in the former but not in the latter (Fig. 2D) .
Assessment of suppressive function indicated that CD4 1 CD127 1 CD25 high cells from both patients (AIH, A4, R18 in Table 1a ; AISC, A1-3, A7, R6, R12 in Table 1b 
CD127
1 CD25 high cells was determined by flow cytometry. Patient numbers in parentheses refer to Table 1a for AIH and to Table 1b 
1 CD25 high cells in patients with AISC (n 5 12; A1-6, R2-4, R7-8, R12) and AIH (n 5 20; AIH, A2-7, A9-10, R1-8, R10-11, R15-16) and in patients with (n 5 10) (AIH, A2, R1, R7; AISC, A2-3, A6, R4, R7-8, R12) and without (n 5 22) (AIH, A3-7, A9-10, R2-6, R8, R10-11, R15-16; AISC, A1, A4-5, R2-3) inflammatory bowel disease. (E) Correlation analysis between the frequency of CD4
1
CD127
1 CD25 high cells and levels (log) of aspartate aminotransferase, total bilirubin, immunoglobulin G, and SMA autoantibody titer and number of relapses. (F) Mean 6 SEM frequency of CD4
1
CD127
1 CD25 high cells in patients treated with prednisolone alone (n 5 7; AIH, R2, R4, R7, R11; AISC, R2, R8, R12), prednisolone and azathioprine (n 5 16; AIH, A2-3, A10, R3, R5-6, R8, R10, R15-16; AISC, A2, A4-5, R3-4, R7), or prednisolone and MMF (n 5 3; AIH, A5, R1; AISC, A6). Abbreviations: A, azathioprine; AST, aspartate aminotransferase; IBD, inflammatory bowel disease; IgG, immunoglobulin G; P, prednisolone.
in the presence of transforming growth factor beta and high-concentration IL-2. This was tested in 14 patients, 3 [A] (AIH, A11-12 in Table 1a ; AISC, A8 in Table 1b ) and 11 [R] (AIH, R9, R13-14, R17-20 in Table 1a ; AISC, R5, R9-11 in Table 1b) , and in 9 HS. Following 4-5 days of polarization, we noted an increase in the proportion of IL-10-producing lymphocytes among CD4 1 CD127
1 CD25 high cells in HS and AIH/AISC patients (Fig. 3A) . Frequencies of IL-10 1 cells within the CD4 1 CD127
1 CD25 high subset were higher in HS than AIH/AISC patients at baseline and after skewing (Fig. 3A) . There was a concomitant decrease in the proportion of CD4 
CD25
high cells expressing IFNc, and this decrease was particularly marked in patients who had a baseline level of IFNc 1 lymphocytes significantly higher than HS (Fig. 3A) . Treg skewing conditions reduced also the frequency of CD4
1
CD127
1 CD25 high cells producing IL-17 in HS and in AIH/AISC patients (Fig. 3A) .
Levels of IL-17-producing cells among CD4
high lymphocytes were higher in AIH/ AISC patients than in HS at baseline and after skewing (Fig. 3A) . When compared to AIH, CD4
high cells from AISC patients displayed higher frequencies of IFNc 1 lymphocytes at baseline (18.5 6 1.9 versus 37.1 6 6.5, P 5 0.04) and lower proportions of IL-17 1 cells after skewing (16.7 6 6 versus 7.7 6 4.3, P 5 0.05).
Given the increase in cells producing IL-10, we sought to determine the expression of CD49b and LAG-3, markers defining Tr1 cells in mice and humans. (18) At baseline the proportion of CD49b (Fig. 3B,C) . Upon exposure to Treg skewing conditions, there was an increase in CD49b 
CD127
1 CD25 high cells display a mixed Th1/Th17 phenotypic profile. Cytokine and transcription factor profile was determined by flow cytometry in AIH/AISC patients and HS. Patient numbers in parentheses refer to Table 1a for AIH and to Table 1b 
1 CD25 high cells exposed to anti-CD3/anti-CD28 beads in the absence or presence of IL-7 in patients (n 5 6; AIH, A2, R4, R8, R11-12; AISC, R1) and HS (n 5 6). Results are presented as mean 6 SEM. Abbreviations: cpm, counts per minute; MFI, mean fluorescence intensity.
FIG. 3. Treg skewing confers CD4
1 CD127
1 CD25 high cells phenotypic properties of Tr1 cells in both autoimmune liver disease patients and HS. CD4 1 CD127
1 CD25 high cells were purified after polarization of CD4 cells under Treg skewing conditions (anti-CD3/anti-CD28, transforming growth factor beta, high-concentration IL-2). Patient numbers in parentheses refer to Table 1a for AIH and to Table  1b 
CD25
high subset was noted between AIH and AISC patients at baseline and after exposure to Treg skewing conditions. These data indicate that exposure to Treg skewing conditions modulates CD4
high cells, which acquire a Tr1-like phenotype by expressing higher levels of IL-10 and heightened CD49b and LAG-3 expression. Table 1a ; AISC, A8 in Table 1b ) and 11 [R] (AIH, R9, R13-14, R17-20 in Table 1a ; AISC, R5, R9-11 in Table 1b ), and in 9 HS. These AIH/AISC patients and HS were the same in whom the effect of Treg skewing on CD4
Treg SKEWING ENDOWS CD4
high cell phenotype was investigated. CD4 
CD25
high cells was present both in HS and in patients, while among CD4 (Fig. 4A) . Levels of pSTAT5 before and after exposure to low-dose IL-2 were lower in patients than in HS, within both the CD4 1 CD127 
2 target cell proliferation more efficiently than their CD127 2 counterparts (Fig. 4B) . Pretreatment with anti-IL-10 neutralizing antibodies decreased CD4
1
CD127
1 CD25 high cell suppression ability in HS but not in patients (Fig. 4B) . Of note, pretreatment with anti-IFNc neutralizing antibodies tended to reduce the CD4 
CD25
high cells in patients but not in HS.
To establish whether the suppressive properties of CD4 1 CD127
1 CD25 high cells after Treg skewing were stably maintained, cells were challenged for 24 hours in the presence of IL-6 and IL-1b, proinflammatory cytokines abundantly expressed by effector CD4 cells in autoimmune liver disease, (12) before reassessing their suppressive function. While CD4
high cells from HS maintained their suppressor ability also after challenge, in AIH and AISC patients they completely lost their ability to control CD4
1
CD25
2 cell proliferation, suggesting the need of maintaining a steady anti-inflammatory environment in order for patient-derived CD4
high cells to retain their ability to suppress (Fig.  4B) Supporting Fig. S1 .
No difference in pSTAT5 expression and in the suppressive ability of CD4
1
CD127
1 CD25 high cells after skewing was noted between AIH and AISC patients.
Collectively these data show that upon Treg skewing CD4
high cells from AIH/AISC patients acquire responsiveness to low-dose IL-2, as well as the ability to suppress target cells. This property appears to be associated with secretion of IFNc and to be completely abrogated upon proinflammatory challenge.
Discussion
The present study shows that CD4 
CD25
high cell frequency to correlate with the number of relapse episodes suggests a possible predictive value of the elevation of this cell subset.
Interestingly, their number is selectively reduced by the addition of MMF to prednisolone, indicating that MMF immunosuppressive activity is at least in part exerted by control over these effector cells. In this context, we have previously observed that in AIH and Table 1a for AIH  and to Table 1b AISC patients treatment with MMF leads to a decrease in the proportion of circulating effector cells in vivo (19) and a decrease in the number of proliferating effectors exposed to mycophenolic acid in vitro. (20) In the absence of cytokine conditioning, CD4 
high cells exposed to Treg polarizing conditions express more IL-10; express drastically less IFNc and, to some extent, IL-17; and acquire Tr1-like phenotypic properties, i.e., coexpression of CD49b and LAG-3. (18) In the experimental setting, transdifferentiation of Th17 cells into IL-10-producing Tr1 cells in the small intestine of mice undergoing experimental colitis has been interpreted as a homeostatic mechanism to control Th17 effector pathogenic potential. (10, 11) Acquisition of Treg phenotypic and functional properties by Teff has also been reported in humans, where conversion of activated CD127
1 effectors into Treg-like cells expressing IFNc was observed, supporting the high plasticity of Teff upon stimulation (21) ; those cells, however, remained CD25 2 rather than being CD25 high as in the present study. Acquisition of regulatory properties by human Teff would not only reduce tissue inflammation but also aid in reestablishing immune tolerance through expansion of the Treg pool. Tr1 cells are key to the control of inflammation during its chronic phase. (22, 23) Thus, in the setting of liver autoimmunity, expansion of the Tr1-like pool of effectors upon Treg skewing might aid in achieving and maintaining immune homeostasis during the inflammatory process, including its chronic phase.
Our data reiterate the importance of reestablishing a regulatory cell pool, which, in the case of AIH and AISC, includes conventional Tregs and cells endowed with Tr1 properties. The pivotal role of regulatory cells in maintaining immune homeostasis in the context of liver autoimmunity has been emphasized in studies showing Treg defects in patients with (24) and animal models of primary biliary cholangitis (25, 26) as well as in individuals suffering from primary sclerosing cholangitis. (27, 28) In AIH and AISC Treg skewing leads CD4 1 cells have enhanced suppressive function, particularly in patients, and gain the ability to respond to low-dose IL-2 by up-regulating pSTAT5. Low-dose IL-2, therefore, might aid in maintaining a modulatory environment by promoting the production of IL-10 by conventional Tregs, as shown, (7) as well as by promoting regulatory properties in Teff. That CD127 1 cells may display suppressor potential has been documented in humans, (15, 29) where they can alternate suppression with secretion of proinflammatory IL-17, depending on the stimulation signals.
Our data show that the mechanism of suppression of CD4 
high cells exert Treg properties also through production of proinflammatory cytokines. IFNc and IL-17 have been shown to be necessary to the development of antigen-specific Tr1 cells in the context of experimental autoimmune encephalomyelitis, insulin-dependent type 1 diabetes, and collagen-induced arthritis, indicating that these cytokines, classically associated with an effector and proinflammatory phenotype, play also a role in the induction of regulatory cell subsets. (30) In the setting of AIH and AISC, IFNc and IL-17 might contribute to the suppressor ability of CD4
1
CD127
1
CD25
high cells by either blocking directly responder cell effector function or indirectly favoring the generation of a "modulatory" environment through IL-10 secretion.
Importantly, in contrast to what observed in HS, CD4 1 CD127
1 CD25 high cells from AIH and AISC patients do not retain suppressive properties in the presence of an inflammatory challenge. This emphasizes the need for maintaining stable control of the inflammatory milieu in order for these cells to exert their suppressive function. Due to the higher plasticity of conventional and induced Tregs in the autoimmune setting, it is crucial to employ therapeutic strategies that create favorable conditions for both Tregs/Tr1 and Teff.
As the present cohort consists mainly of patients with juvenile-onset AIH or AISC, with an unusually equal sex distribution and a relatively high incidence of inflammatory bowel disease, probably reflecting our active screening policy, (2) our findings cannot be immediately applied to adult AIH and sclerosing cholangitis. Though in a previous study we found that age does not influence effector and Treg immune responses, (6) investigation of a larger number of adults and children with AIH/AISC is needed to address the impact of age and gender on T-cell immunity and to elucidate further the immunophenotypic differences we have observed between AIH and AISC in this study (baseline levels of IFNc and postskewing levels of IL-17 produced by CD4 1 CD127
1 CD25 high cells) and in a previous report (levels of CD39 in Th17 cells). (19) In summary, we provide evidence that in AIH and AISC activated CD4 
CD127
1 CD25 high Teff are likely to play a major damaging role, but following Treg conditioning they acquire immune modulatory Tr1-like properties. However, stability of the cytokine milieu is key to the maintenance of an effective T regulatory pool not only through the expansion of already existing Tregs but also through the skewing of Teff into Treg/Tr1 cells. Successful control of T-cell plasticity would help in the reshaping of Teff/Treg interactions in autoimmunity and would contribute to generating stable and long-lasting tolerance.
